Related Experiment Video
Updated: Jul 12, 2026

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats
Published on: November 20, 2015
Infant perinatal thrombosis and antiphospholipid antibodies: a review
1Service d'Hématologie, Hopital Jean Verdier, Assistance publique, Hospitaux de Paris, Bondy, France. marieclaire.boffa@wanadoo.fr
Insights
Infants born to mothers with antiphospholipid antibodies (aPL) face a risk of perinatal thrombosis, primarily arterial strokes. Early detection of aPL in neonates and investigation of maternal risk factors are crucial for prevention and management.
Area of Science:
- Neonatology
- Hematology
- Obstetrics
Background:
- Perinatal thrombosis in infants of mothers with antiphospholipid antibodies (aPL) is rare but severe.
- Antiphospholipid antibodies (aPL) can increase the risk of thrombosis in newborns.
Purpose of the Study:
- To analyze perinatal thrombosis cases in infants born to mothers with aPL.
- To identify risk factors and outcomes associated with perinatal thrombosis in this population.
Main Methods:
- Literature review of 16 infants with perinatal thrombosis and maternal aPL over 20 years.
- Analysis of thrombosis type, location, associated risk factors, and neonatal antiphospholipid syndrome (APS).
Main Results:
- Arterial thromboses, mainly strokes, were most common (13/16).
- Additional risk factors like preeclampsia, IUGR, asphyxia, sepsis, or catheters were present in 9/14 infants.
- Five infants had aPL as the sole risk factor, with four experiencing stroke.
- Neonatal APS was observed in 11 infants, with matching antibodies in mother and child.
Conclusions:
- Women with aPL require investigation for additional thrombophilic risk factors.
- Systematic screening for aPL in newborns of mothers with APS is recommended.
Abstract:
Perinatal thrombosis in infants born to mothers with antiphospholipid antibodies (aPL) is a rare event, but with risk of death or severe sequelae. We analysed 16 infants with such perinatal thrombosis reported in the literature in the last 20 years. Thromboses were arterial (13/16), mostly strokes (8/16). Hydrops fetalis with left renal vein thrombosis was associated to a lupus anticoagulant (LA) present only in the child. Risk factors additional to aPL: either prenatal (preeclampsia and/or intra-uterine growth retardation) or perinatal (asphyxia, sepsis, arterial or venous catheter and congenital thrombophilia) were present (one to four of them) in nine out of the 14 evaluable babies. aPL were the only risk factor found in five full term babies who suffered from stroke in four cases and from renal thrombosis in another. Eleven of these infants with aPL in their serum presented a neonatal APS with the same antibody (LA or aCL IgG) found in neonates and their mothers, while the other infants had thrombosis with aPL only in their mother's blood. aCL IgM was only found in one neonate who suffered from sepsis. Thrombosis treatments were diverse. This analysis suggests that women with aPL should be investigated for other thrombophilic risk factors and that aPL should be detected systematically at birth in the offspring of mothers with APS.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Development of Immunocompetence
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
Transcytosis of IgG
IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis I: Introduction
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.